Key Points Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its ...

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo Nordisk and UnitedHealth Group have been beaten down to less than half their ...

Omega Fund VIII, was oversubscribed and beat its $600 million target, reaching the hard cap. With Fund VIII, the firm will continue to execute its strategy of creating and investing in life sciences ...

Eli Lilly (LLY) ended the recent trading session at $762.18, demonstrating a -1.23% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14% ...

ADI shares flashed a Golden Cross pattern on July 1, when the 50-day moving average crossed above the 200-day, a classic ...

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

The largest healthcare stocks by market capitalization are undergoing significant sell-offs. UnitedHealth is still a large ...

Rhythm Pharmaceuticals develops medicines for rare disorders that cause weight gain. The company's only approved product is ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

Novo Nordisk sees solid Q1 results, major GLP-1 growth potential, and limited downside despite guidance cut and rising risks.

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...